Blocking early complement activation prevents microglia-mediated excessive synapse loss before and during amyloid deposition. C1q localized to synapses in early AD correlates with cognitive decline; C3 knockout or CR3 deficiency protects synapses in 5xFAD mice. Annexon's ANX005 anti-C1q antibody has human CNS target engagement experience from Huntington's disease trials.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Neuroinflammationneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
7/11
dimensions won
NLRP3 Inflammasome Inhibition for Neurop
4/11
dimensions won
Complement C1q/C3 Inhibition to Prevent
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.70
0.80
Evidence
0.72
0.78
Novelty
0.65
0.55
Feasibility
0.78
0.62
Impact
0.75
0.82
Druggability
0.80
0.75
Safety
0.65
0.52
Competition
0.70
0.65
Data
0.75
0.72
Reproducible
0.68
0.70
KG Connect
0.60
0.50
Score Breakdown
Dimension
NLRP3 Inflammasome Inhibition
Complement C1q/C3 Inhibition t
Mechanistic
0.700
0.800
Evidence
0.720
0.780
Novelty
0.650
0.550
Feasibility
0.780
0.620
Impact
0.750
0.820
Druggability
0.800
0.750
Safety
0.650
0.520
Competition
0.700
0.650
Data
0.750
0.720
Reproducible
0.680
0.700
KG Connect
0.599
0.500
Evidence
NLRP3 Inflammasome Inhibition for Neuroprotection in Parkins
No evidence citations yet
Complement C1q/C3 Inhibition to Prevent Synaptodendritis in
No evidence citations yet
Debate Excerpts
NLRP3 Inflammasome Inhibition for Neuroprotection
4 rounds · quality: 0.75
Persona-Theorist
# Therapeutic and Mechanistic Hypotheses in Neurodegeneration
## Hypothesis 1: TREM2 Activation as a Therapeutic Strategy for Alzheimer's Disease
**Mechanism:** Loss-of-function TREM2 variants impai...
As of April 2026, I would treat these as **three translationally viable programs**, **two discovery-stage mechanisms**, and **two deprioritized concepts**.
**Feasibility Ranking**
| Rank | Hypothesi...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "NLRP3 Inflammasome Inhibition for Neuroprotection in Parkinson's Disease",
"description": "Targeted inhibition of NLRP3 inflammasome activation a...
Complement C1q/C3 Inhibition to Prevent Synaptoden
4 rounds · quality: 0.75
Persona-Theorist
# Therapeutic and Mechanistic Hypotheses in Neurodegeneration
## Hypothesis 1: TREM2 Activation as a Therapeutic Strategy for Alzheimer's Disease
**Mechanism:** Loss-of-function TREM2 variants impai...
As of April 2026, I would treat these as **three translationally viable programs**, **two discovery-stage mechanisms**, and **two deprioritized concepts**.
**Feasibility Ranking**
| Rank | Hypothesi...
Persona-Synthesizer
{
"ranked_hypotheses": [
{
"title": "NLRP3 Inflammasome Inhibition for Neuroprotection in Parkinson's Disease",
"description": "Targeted inhibition of NLRP3 inflammasome activation a...